PCSK9 and colorectal carcinoma: Studies have also reported that the PCSK9 inhibitor and HMGCR suppressor statins possess anti-CRC effects (Navarese et al., 2015; Gu et al., 2022; Shailes et al., 2022), which further stand for the potential pivotal role of mTOR signal mediation by ezetimibe in CRC.